• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.

作者信息

Zhang Xueya, Guo Xizhe

机构信息

Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, 34 Zhongshan North Road, Quanzhou, 362000, Fujian Province, China.

出版信息

Ann Hematol. 2019 Sep;98(9):2223-2225. doi: 10.1007/s00277-019-03674-2. Epub 2019 Apr 12.

DOI:10.1007/s00277-019-03674-2
PMID:30980106
Abstract
摘要

相似文献

1
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.地西他滨、伊达比星、阿糖胞苷和粒细胞集落刺激因子联合（DIAG）方案治疗高危骨髓增生异常综合征和急性髓系白血病。
Ann Hematol. 2019 Sep;98(9):2223-2225. doi: 10.1007/s00277-019-03674-2. Epub 2019 Apr 12.
2
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.地西他滨诱导的表观遗传学重编程序贯低剂量伊达比星和阿糖胞苷治疗由骨髓增生异常综合征和高危骨髓增生异常综合征进展而来的急性髓系白血病：一项前瞻性多中心单臂试验。
Hematol Oncol. 2020 Oct;38(4):531-540. doi: 10.1002/hon.2755. Epub 2020 Jun 24.
3
Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.小剂量阿糖胞苷、高三尖杉酯碱联合粒细胞集落刺激因子预处理方案对骨髓增生异常综合征或骨髓增生异常综合征转化的急性髓系白血病患者的疗效。
Leuk Lymphoma. 2009 Sep;50(9):1461-7. doi: 10.1080/10428190903096719.
4
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.与传统化疗相比，在高危骨髓肿瘤中，先用地西他滨进行表观遗传启动，再给予低剂量伊达比星/阿糖胞苷，具有增强的抗白血病作用。
Leuk Lymphoma. 2016;57(6):1311-8. doi: 10.3109/10428194.2015.1091931. Epub 2015 Oct 13.
5
Treatment of myelodysplastic syndromes with AML-type chemotherapy.采用急性髓系白血病（AML）型化疗方案治疗骨髓增生异常综合征。
Leuk Lymphoma. 1993;11 Suppl 2:59-63. doi: 10.3109/10428199309064263.
6
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.粒细胞集落刺激因子预激、氯法拉滨及大剂量阿糖胞苷（GCLAC）用于急性髓系白血病、晚期骨髓增生异常综合征或晚期骨髓增殖性肿瘤的初始治疗。
Am J Hematol. 2015 Apr;90(4):295-300. doi: 10.1002/ajh.23927. Epub 2015 Jan 30.
7
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星（FLAG-IDA）用于治疗高危骨髓增生异常综合征和急性髓系白血病。
Br J Haematol. 1997 Dec;99(4):939-44. doi: 10.1046/j.1365-2141.1997.4763281.x.
8
Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.地西他滨诱导化疗后血小板计数的早期恢复是老年新发急性髓系白血病患者对治疗反应良好的预后标志物。
BMC Cancer. 2018 Dec 19;18(1):1269. doi: 10.1186/s12885-018-5160-5.
9
Wernicke's Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Study.一名急性髓系白血病患者的韦尼克脑病：病例报告
Turk J Haematol. 2016 Mar 5;33(1):78-9. doi: 10.4274/tjh.2015.0249.
10
How I treat older patients with acute myeloid leukemia.我如何治疗老年急性髓系白血病患者。
Cancer. 2018 Jun 15;124(12):2472-2483. doi: 10.1002/cncr.31347. Epub 2018 May 29.

引用本文的文献

1
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.单中心 PD-1 抑制剂联合 DNA 低甲基化剂+ CAG 方案治疗复发/难治性急性髓系白血病的 2 期临床研究。
Cancer Immunol Immunother. 2023 Aug;72(8):2769-2782. doi: 10.1007/s00262-023-03454-y. Epub 2023 May 11.
2
A novel biocompatible Eu-based coordination polymers of cytarabine anticancer drug: Preparation, luminescence properties and anticancer activity studies.一种新型阿糖胞苷抗癌药物的生物相容性铕基配位聚合物：制备、发光性质及抗癌活性研究
Front Chem. 2022 Nov 11;10:1043810. doi: 10.3389/fchem.2022.1043810. eCollection 2022.